The approval of Biogen Idec’s MS therapy Tecfidera follows months of breathless Wall Street hype, and it looks like doctors are psyched for the drug, too. In a MedLIVE PULSE survey conducted by WorldOne...
Mortality risk increased for MS patients soon after CRC diagnosis
Sep 16, 2021
Associations between MS and all-cause, cancer-specific death partially attenuated after adjustment for disability status